StreetAlpha.app
Home › Stocks › GKOS

GLAUKOS Corp (GKOS)

Healthcare
$243.34
▼ −0.65%
LAST CLOSE · NOV 17

Glaukos develops and sells eye treatments, including glaucoma stents and drug implants, for ophthalmologists and other eye care professionals. It last closed at $243.34 on Nov 17, down 0.65% on the day. GKOS last reported earnings on Wed, Oct 28, 2026. The average 12-month price target from 10 analysts is $239.40 (-1.6% from the last close), with a high of $255.00 and a low of $210.00. Analyst consensus is Strong Buy, based on the latest ratings from 10 firms (10 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 7 whale options trades in GKOS, 71% of them bullish and 29% bearish. In the past 30 days there were 5 dark pool prints totaling $6.8M, the largest $2.4M.

AI Auto Pilots
Is GKOS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$690.3M
+46.9% vs a year ago
Net income
−$169.8M
−24.6% margin
EPS (diluted)
−$2.95
Free cash flow
$36.0M
5.2% margin
Valuation
Market cap
$14.4B
59.2M shares
P/E
–
No P/E while losing money
Price to sales
20.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$162.3M
At Sep 30
Shareholder equity
$717.3M
Shares outstanding
59.2M
At Oct 26
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $294.0M$294.0MFY2021FY2022: $282.9M$282.9MFY2022FY2023: $314.7M$314.7MFY2023FY2024: $383.5M$383.5MFY2024FY2025: $507.4M$507.4MFY2025

From GKOS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 28). Last 12 months adds up the four latest quarters.

Last report
Oct 28
2026 · After the close (AMC)
Reported EPS
$0.47
vs -$0.12 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±14.8%
Priced in before that report
Analyst consensus
Strong Buy
Based on 10 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
10firms
10 Buy0 Hold0 Sell
Each firm's latest rating on GKOS in the past 90 days
Average 12-month target
$239.40
▼ 1.6% downside

Based on 10 analysts who set a price target on GKOS in the past 90 days. The average target is $239.40, with a high of $255.00 and a low of $210.00, compared with the last close of $243.34.

Low $210.00Avg $239.40High $255.00
Blue marker: last close $243.34
Highest target$255.00
Average target$239.40
Lowest target$210.00
Latest rating changes
BTIGTarget raised
Nov 16Buy$234 → $252
HC Wainwright & Co.Target raised
Oct 29Buy$195 → $248
JP MorganMaintained
Oct 29Buy$240
CitigroupTarget raised
Oct 29Buy$188 → $247
Truist SecuritiesTarget raised
Oct 29Buy$215 → $255
DateFirmActionRatingPrice target
Nov 16BTIGTarget raisedBuy$234 → $252
Oct 29HC Wainwright & Co.Target raisedBuy$195 → $248
Oct 29JP MorganMaintainedBuy$240
Oct 29CitigroupTarget raisedBuy$188 → $247
Oct 29Truist SecuritiesTarget raisedBuy$215 → $255
Loading…

Technical Analysis

GKOS · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 9% above its 20 day and 23% above its 50 day average. It is 39% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 67), near overbought. The nearest support is the Pivot S1 at $239.75, and the nearest resistance the Pivot at $243.40.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 4.6%/day
Key levels
$255.1952 week high+4.9%
$255.19Swing high (Nov 4)+4.9%
$247.00Pivot R1+1.5%
$243.40Pivot+0.0%
$243.34Last close
$239.75Pivot S1−1.5%
$220.9120 day average−9.2%
$218.98Swing low (Nov 5)−10.0%
$187.1350 day average−23.1%
$177.30100 day average−27.1%
$148.52200 day average−39.0%
$87.3252 week low−64.1%
Indicators
RSI (14)66.87Strong, overbought above 70Neutral
MACD18.25Above its signal lineBullish
Stochastic83.6Near the top of its rangeOverbought
ADX (14)42.6Strong uptrend
Williams %R-24.8Oversold below −80, overbought above −20Neutral
CCI (20)59.9Oversold below −100, overbought above 100Neutral
Rate of change+4.4%Change over 10 sessionsBullish
ATR (14)$11.29Typical daily range, 4.6% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for GKOS

What happened before

See how GKOS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bullish5 bullish and 2 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow GKOS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GKOS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
7
Bullish
5
71%
Bearish
2
29%
Date span
Sep 10 – Nov 16
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
5
Notional
$6.8M
Largest print
$2.4M
Loading…

GKOS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲230 buying vs 176 selling
  • ▼Held by funds -2.6 pts
  • ▲Funds holding +54
  • ▲Superinvestors: 3 added, 2 cut
  • ▼Put/call 2.12 to 2.67
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding422368+14.7%
In funds' top 1052+150.0%
Held by funds100.3%102.9%−2.6 pts
New / increased89 / 14168 / 147+7.0%
Reduced / sold out141 / 35101 / 39+25.7%
Put/call ratio2.672.12+25.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GKOS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GKOS is in one of them and how their past GKOS trades turned out.

GKOS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GKOS in an article yet. Here's the latest on the wider market.

GKOS Congress Trades

All congress trades →
Trades, 12 months
5
Buys
2
40%
Sells
2
40%
People
1
Last filed Sep 22
Who traded GKOS · since 2026
Latest 5 filings
$50K – $100KTraded Jul 29, 2026Filed Sep 22, 2026
$15K – $50KTraded May 15, 2026Filed Jul 1, 2026
$15K – $50KTraded Mar 30, 2026Filed May 14, 2026
$1K – $15KTraded Feb 26, 2026Filed May 14, 2026
$15K – $50KTraded Jan 26, 2026Filed May 14, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$50K – $100KJul 29, 2026Sep 22, 202655 d
Donald J TrumpExecutive branchSell$15K – $50KMay 15, 2026Jul 1, 202647 d
Donald J TrumpExecutive branchBuy$15K – $50KMar 30, 2026May 14, 202645 d
Donald J TrumpExecutive branchOther$1K – $15KFeb 26, 2026May 14, 202677 d
Donald J TrumpExecutive branchBuy$15K – $50KJan 26, 2026May 14, 2026108 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About GLAUKOS

Glaukos is an ophthalmic pharmaceutical and medical technology company based in Aliso Viejo, California. It makes procedural treatments for glaucoma, including small stents placed during eye surgery and a drug implant that releases medication inside the eye over time. It also sells treatments that strengthen the cornea for corneal disorders such as keratoconus, and it is developing therapies for retinal disease. Its customers are ophthalmologists and other eye care professionals.

Headquarters
Aliso Viejo, CA